Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Change in Acquisitions & Divestments: 2023-2025

Historic Change in Acquisitions & Divestments for IDEAYA Biosciences (IDYA) over the last 3 years, with Sep 2025 value amounting to $180.8 million.

  • IDEAYA Biosciences' Change in Acquisitions & Divestments fell 6.87% to $180.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $682.3 million, marking a year-over-year increase of 3.06%. This contributed to the annual value of $692.6 million for FY2024, which is 57.45% up from last year.
  • As of Q3 2025, IDEAYA Biosciences' Change in Acquisitions & Divestments stood at $180.8 million, which was up 3.83% from $174.1 million recorded in Q2 2025.
  • IDEAYA Biosciences' Change in Acquisitions & Divestments' 5-year high stood at $234.3 million during Q2 2024, with a 5-year trough of $95.9 million in Q1 2023.
  • For the 3-year period, IDEAYA Biosciences' Change in Acquisitions & Divestments averaged around $152.2 million, with its median value being $141.0 million (2024).
  • In the last 5 years, IDEAYA Biosciences' Change in Acquisitions & Divestments soared by 134.88% in 2024 and then dropped by 25.68% in 2025.
  • Over the past 3 years, IDEAYA Biosciences' Change in Acquisitions & Divestments (Quarterly) stood at $110.5 million in 2023, then grew by 27.63% to $141.0 million in 2024, then decreased by 6.87% to $180.8 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $180.8 million for Q3 2025, versus $174.1 million for Q2 2025 and $186.4 million for Q1 2025.